Detailed Information on Publication Record
2011
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 2.
DWYER, Michael, Kamil PARUCH, Marc LABROLI, Carmen ALVAREZ, Kerry KEERTIKAR et. al.Basic information
Original name
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 2.
Name in Czech
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 2.
Authors
DWYER, Michael (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor, belonging to the institution), Marc LABROLI (840 United States of America), Carmen ALVAREZ (840 United States of America), Kerry KEERTIKAR (840 United States of America), Cory POKER (840 United States of America), Randall ROSSMAN (840 United States of America), Thierry FISCHMANN (840 United States of America), Jose DUCA (840 United States of America), Vincent MADISON (840 United States of America), David PARRY (840 United States of America), Nicole DAVIS (840 United States of America), Wolfgang SEGHEZZI (840 United States of America), Derek WISWELL (840 United States of America) and Timothy GUZI (840 United States of America)
Edition
Bioorganic & Medicinal Chemistry Letters, Elsevier, 2011, 0960-894X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10401 Organic chemistry
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.554
RIV identification code
RIV/00216224:14310/11:00055928
Organization unit
Faculty of Science
UT WoS
000285544400097
Keywords in English
Kinase CHK1 Pyrazolo[1 5-a]pyrimidine Template
Změněno: 5/3/2012 11:30, Ing. Zdeňka Rašková
Abstract
V originále
Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo [1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors.